Literature DB >> 17932507

Post-operative complication of trabeculectomy in Ibadan, Nigeria: outcome of 1-year follow-up.

A O Ashaye1, O O Komolafe.   

Abstract

OBJECTIVE: To describe the post-operative complications reported in patients who had trabeculectomy with and without antimetabolite in UCH, Ibadan between 1999 and 2003 and the success rate achieved in term of the post-operative intraocular pressure (IOP).
METHODS: A retrospective study of the records of glaucoma patients who had trabeculectomy between 1999 and 2003 and had follow-up in UCH Ibadan eye clinic for a minimum of 1 year was carried out.
RESULTS: Seventy-six out of 171 eyes that had trabeculectomy during the period were reviewed. Mean age of patients was 49.4 years. The mean preoperative IOP was 31.8 mm Hg. Success rate of 79.4% was achieved in term of IOP control at a year of follow-up. The most frequent early post-operative complication was shallow AC (13 eyes; 17.1%) while late complication was elevated IOP (21 eyes; 27.6%). Others were encapsulated bleb 7.9% and hyphema 3.9%. There was no significant difference in the complication rate in those who had intraoperative antimetabolite (5-fluorouracil) when compared with those operated without antimetabolite.
CONCLUSION: Guarded filtration surgery is effective in controlling IOP. Most of the complications noted were transient and not visually threatening.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932507     DOI: 10.1038/sj.eye.6702979

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  9 in total

1.  A comparative study of mitomycin C and 5-Fluorouracil trabeculectomy in west Africa.

Authors:  Nitin Anand; Vinod K Dawda
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

2.  Is Beta Radiation Better than 5 Flurouracil as an Adjunct for Trabeculectomy Surgery When Combined with Cataract Surgery? A Randomised Controlled Trial.

Authors:  Kazim Dhalla; Simon Cousens; Richard Bowman; Mark Wood; Ian Murdoch
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

3.  Incidence of short-term complications and associated factors after primary trabeculectomy in Chiang Mai University Hospital.

Authors:  Thidarat Leeungurasatien; Preeyanuch Khunsongkiet; Kassara Pathanapitoon; Damrong Wiwatwongwana
Journal:  Indian J Ophthalmol       Date:  2016-10       Impact factor: 1.848

4.  What Glaucoma Surgical Rate could Serve as a Target for West Africa? A Systematic Review.

Authors:  Egbula N Eni; Winifred Nolan; Bassey Eval; John C Buchan
Journal:  J Curr Glaucoma Pract       Date:  2021 Jan-Apr

5.  LONG TERM OUTCOMES OF AUGMENTED TRABECULECTOMY WITH 5-FLUOROURACIL IN NIGERIA.

Authors:  O O Olawoye; A O Ashaye
Journal:  J West Afr Coll Surg       Date:  2017 Jan-Mar

6.  Evaluation of recurrent hyphema after trabeculectomy with ultrabiomicroscopy 50-80 MHz: a case report.

Authors:  Giuseppe Mannino; Sara Verrilli; Silvia Calafiore; Angela Ciarnella; Alessandro Cutini; Cristina Mannino; Andrea Perdicchi; Santi Maria Recupero
Journal:  BMC Res Notes       Date:  2012-10-04

7.  Outcomes of trabeculectomy with 5-Fluorouracil at a nigerian tertiary hospital.

Authors:  Olusola O Olawoye; Adeyinka O Ashaye; Aderonke M Baiyeroju; Christopher C Teng; Jeffrey M Liebmann; Robert Ritch
Journal:  J Ophthalmic Vis Res       Date:  2013-04

8.  Randomized Clinical Trial for Early Postoperative Complications of Ex-PRESS Implantation versus Trabeculectomy: Complications Postoperatively of Ex-PRESS versus Trabeculectomy Study (CPETS).

Authors:  Shogo Arimura; Yuji Takihara; Seiji Miyake; Kentaro Iwasaki; Makoto Gozawa; Takehiro Matsumura; Takeshi Tomomatsu; Yoshihiro Takamura; Masaru Inatani
Journal:  Sci Rep       Date:  2016-05-17       Impact factor: 4.379

9.  Silencing of ILK attenuates the abnormal proliferation and migration of human Tenon's capsule fibroblasts induced by TGF-β2.

Authors:  Yao Xing; Lijun Cui; Qianyan Kang
Journal:  Int J Mol Med       Date:  2016-06-16       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.